The male patient had been enrolled in the ALPHA3 trial, in which Allogene is evaluating a novel CAR-T therapy for diffuse large B-cell lymphoma (DLBCL), according to Fierce Biotech.
The death occurred nearly two months after the patient received treatment, which included the experimental antibody ALLO-647 alongside standard lymphodepletion drugs. According to the company, the CAR-T cells were not responsible for the fatal outcome; instead, ALLO-647 is believed to have caused severe immunosuppression. The patient ultimately died of liver failure, likely due to a disseminated adenovirus infection.
BREAKING